AURA250117P7500
- 0.35
- 0.000.00%
Aura Biosciences Newsroom
Buy Recommendation for Aura Biosciences Inc. Based on Promising Clinical Data and Growth Prospects
Aura Biosciences Price Target Lowered to $21 From $23 at JMP Securities
Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
BTIG Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $24
Scotiabank Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $23
Aura Biosciences Analyst Ratings
TD Cowen Maintains Aura Biosciences(AURA.US) With Buy Rating
LifeSci Capital Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $23
Buy Rating for Aura Biosciences Inc Driven by Promising Clinical Progress and Strategic Growth
Express News | Aura Biosciences Q3 EPS $(0.42) Beats $(0.45) Estimate
Express News | Aura Biosciences Inc -Strong Cash Position Expected to Support Operations Into 2H 2026
Aura Biosciences 3Q Loss/Shr 42c >AURA
Aura Biosciences | 10-Q: Q3 2024 Earnings Report
Aura Biosciences | 8-K: Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
Express News | Aura Biosciences Q3 Operating Expenses USD 23.232 Million
Press Release: Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
One Aura Biosciences Insider Raised Stake By 232% In Previous Year
A Quick Look at Today's Ratings for Aura Biosciences(AURA.US), With a Forecast Between $20 to $24
Aura Biosciences Up Over 13%, on Pace for Largest Percent Increase Since November 2023 -- Data Talk